AlloVir reports $248.1M cash at year-end 2021; JPM presentation ongoing

Kalaris Therapeutics, Inc.

Unaudited cash, equivalents and marketable securities total $248.1M as of Dec 31, 2021.
Corporate presentation furnished for J.P. Morgan Healthcare Conference on Jan 10, 2022.
AlloVir is a leader in allogeneic, off-the-shelf virus-specific T cell therapies.

item 2.02 item 7.01 item 9.01

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-005069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.